ASR Vermogensbeheer N.V. Acquires Shares of 228,860 Johnson & Johnson (NYSE:JNJ)

Key Points

• ASR Vermogensbeheer N.V. acquired a new stake in Johnson & Johnson, purchasing 228,860 shares valued at approximately $37.96 million.
• Johnson & Johnson reported a net margin of 25.00% and a return on equity of 32.49%, with revenue of $23.74 billion for the last quarter.
• The company announced a quarterly dividend of $1.30, yielding approximately 3.0%, set to be paid to investors on September 9th.

ASR Vermogensbeheer N.V. bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 228,860 shares of the company's stock, valued at approximately $37,955,000.

Several other institutional investors have also recently bought and sold shares of the business. Bernard Wealth Management Corp. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $36,000. Highline Wealth Partners LLC boosted its position in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. von Borstel & Associates Inc. bought a new position in Johnson & Johnson in the 1st quarter valued at $49,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at $52,000. Finally, Capital A Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $50,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research analyst reports. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Morgan Stanley upped their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. UBS Group raised their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Finally, Barclays upped their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Price Performance

NYSE:JNJ traded up $0.82 during trading hours on Thursday, hitting $171.41. 9,314,579 shares of the company's stock traded hands, compared to its average volume of 9,367,092. The firm has a market cap of $412.81 billion, a P/E ratio of 18.33, a P/E/G ratio of 2.17 and a beta of 0.41. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The business's fifty day simple moving average is $158.89 and its two-hundred day simple moving average is $157.27. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $172.18.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm's revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.